Shilpa Medicare secures Orion for European nivolumab biosimilar commercialization and supply
Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.
Pharma & Biotech
Pharma & Biotech
Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
Ono’s ONO-4578 improved gastric cancer PFS in Phase 2. The next test is whether EP4 blockade can survive global Phase 3 scrutiny.
Pharma & Biotech
Imneskibart enters the ASCO spotlight as Aulos Bioscience tests a smarter IL-2 strategy in melanoma
Aulos Bioscience will present new imneskibart melanoma data at ASCO 2026. Read what it could mean for IL-2 therapy and immuno-oncology.
Pharma & Biotech
How Bristol Myers Squibb’s Opdivo approvals in frontline and relapsed classical Hodgkin lymphoma reset treatment pathways
Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.
Pharma & Biotech
Can nivolumab plus AVD become the new frontline treatment in classical Hodgkin lymphoma?
FDA fast-tracks review of Opdivo plus AVD for first-line Hodgkin lymphoma. Find out what this immunotherapy combo could change for patients and providers.